NCT03412877 2026-03-17
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
36 trialsNCT05231122 2026-03-16
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT01174121 2026-03-04
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06083844 2026-03-04
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04781088 2026-02-11
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07261683 2025-12-19
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University
Phase 2 Recruiting
NCT03797326 2025-11-17
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT05446870 2025-10-01
MK-4830-002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03029403 2025-09-19
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04387227 2025-09-18
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 2 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05446298 2025-07-29
PRESERVE-004
OncoC4, Inc.
Phase 2 Active not recruiting
NCT04575961 2025-05-23
PERCEPTION
North Eastern German Society of Gynaecological Oncology
Phase 2 Active not recruiting
NCT04919629 2025-05-11
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT04713514 2024-12-02
TEDOVA
ARCAGY/ GINECO GROUP
Phase 2 Active not recruiting
NCT03602586 2024-07-26
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03732950 2024-04-15
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03012620 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT02766582 2024-02-26
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT02901899 2024-02-20
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Northwestern University
Phase 2 Completed
NCT04417192 2023-07-06
OLAPem
National Cancer Center Hospital East
Phase 2 Completed
NCT04519151 2023-06-08
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
Phase 2 Recruiting
NCT03410784 2023-03-24
MITO28MaNGOov4
National Cancer Institute, Naples
Phase 2 Unknown
NCT03430700 2023-01-30
PROMPT
University College, London
Phase 2 Unknown
NCT03428802 2022-11-18
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT02440425 2022-10-07
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02865811 2022-09-13
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02499952 2022-07-11
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Hoosier Cancer Research Network
Phase 2 Terminated
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT03836352 2022-03-31
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2 Active not recruiting
NCT02674061 2022-03-24
KEYNOTE-100
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02608684 2022-03-23
PemCiGem
Cedars-Sinai Medical Center
Phase 2 Completed
NCT04375956 2021-12-20
MITO 27
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT02853318 2021-10-06
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT03539328 2018-05-29
MITO27
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown